Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FDG PET in Dilated Cardiomyopathy
NCT02078141Completed
- Sponsor
- CHU de Nantes
- Start
- Jun 2014
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of fludeoxyglucose f 18 in dilated cardiomyopathy (DCM), sponsored by CHU de Nantes. Primary endpoint: Percentage of patients with a diagnostic potential of the 18F-FDG PET in the detection of a significant non-cardiomyocyte hypermetabolism at 12 months. Started Jun 2014; status: completed.
02
Drugs
fludeoxyglucose f 18
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on NCT02078141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02078141.